Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZIMMER BIOMET HOLDINGS, INC.

(ZBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zimmer Biomet : 2020 and 2019

05/04/2021 | 10:33am EDT

ZIMMER BIOMET HOLDINGS, INC.

NET SALES - YEARS ENDED DECEMBER 31, 2020 and 2019

(in millions, unaudited)

2019

2020

Q1

Q2

Q3

Q4

Year

Q1

Q2

Q3

Q4

Year

Geographic Results

Americas

$

1,194.1

$

1,214.3

$

1,179.2

$

1,288.2

$

4,875.8

$

1,101.3

$

733.7

$

1,216.5

$

1,283.9

$

4,335.4

EMEA

463.9

438.0

374.6

470.4

1,746.9

398.1

218.7

366.2

408.3

1,391.3

Asia Pacific

317.5

336.3

338.6

367.1

1,359.5

284.4

273.7

346.6

393.1

1,297.8

Total

$

1,975.5

$

1,988.6

$

1,892.4

$

2,125.7

$

7,982.2

$

1,783.8

$

1,226.1

$

1,929.3

$

2,085.3

$

7,024.5

Product Categories

Knees

Americas

$

405.9

$

405.7

$

389.9

$

443.9

$

1,645.4

$

378.1

$

220.7

$

400.4

$

445.5

$

1,444.7

EMEA

175.6

163.8

135.5

175.7

650.6

152.7

65.4

126.2

141.3

485.6

Asia Pacific

110.9

127.2

120.0

126.5

484.6

97.9

88.9

121.9

139.3

448.0

Total

692.4

696.7

645.4

746.1

2,780.6

628.7

375.0

648.5

726.1

2,378.3

Hips

Americas

247.1

253.3

249.0

266.9

1,016.3

232.5

170.7

268.6

269.7

941.5

EMEA

133.1

125.9

108.8

132.0

499.8

111.4

70.8

109.7

115.9

407.8

Asia Pacific

103.2

99.3

101.4

111.5

415.4

88.7

88.2

105.8

118.5

401.2

Total

483.4

478.5

459.2

510.4

1,931.5

432.6

329.7

484.1

504.1

1,750.5

S.E.T*

406.2

408.7

400.6

437.0

1,652.5

380.9

292.7

417.1

434.9

1,525.6

Spine & Dental

253.5

257.6

241.2

269.5

1,021.8

219.5

152.3

253.4

271.8

897.0

Other

140.0

147.1

146.0

162.7

595.8

122.1

76.4

126.2

148.4

473.1

Total

$

1,975.5

$

1,988.6

$

1,892.4

$

2,125.7

$

7,982.2

$

1,783.8

$

1,226.1

$

1,929.3

$

2,085.3

$

7,024.5

* Sports Medicine, Extremities, Trauma and CMFT

ZIMMER BIOMET HOLDINGS, INC.

PRODUCT CATEGORY CHANGE IN NET SALES FROM PREVIOUS PRESENTATION

(in millions, unaudited)

2019

2020

Q1

Q2

Q3

Q4

Year

Q1

Q2

Q3

Q4

Year

Product Categories

Knees

Americas

$

(3.3)

$

(8.8)

$

(9.3)

$

(9.8)

$

(31.2)

$

(2.2)

$

(0.3)

$

(2.2)

$

(11.7)

$

(16.4)

EMEA

(0.1)

0.4

0.2

(4.0)

(3.5)

-

0.2

(0.4)

(1.2)

(1.4)

Asia Pacific

1.7

1.6

2.6

(0.7)

5.2

1.1

0.9

2.4

1.9

6.3

Total

(1.7)

(6.8)

(6.5)

(14.5)

(29.5)

(1.1)

0.8

(0.2)

(11.0)

(11.5)

Hips

Americas

-

-

-

-

-

-

-

-

-

-

EMEA

-

-

-

-

-

-

-

-

-

-

Asia Pacific

-

-

-

-

-

-

-

-

-

-

Total

-

-

-

-

-

-

-

-

-

-

S.E.T*

49.4

51.7

52.1

55.2

208.4

47.3

40.1

57.2

59.0

203.6

Spine & Dental

(33.8)

(34.8)

(34.3)

(36.6)

(139.5)

(32.2)

(30.2)

(42.1)

(42.2)

(146.7)

Other

(13.9)

(10.1)

(11.3)

(4.1)

(39.4)

(14.0)

(10.7)

(14.9)

(5.8)

(45.4)

Total

$

-

$

-

$

-

$

-

$

-

$

-

$

-

$

-

$

-

$

-

* Sports Medicine, Extremities, Trauma and CMFT

ZIMMER BIOMET HOLDINGS, INC.

NET SALES % CHANGE - YEAR ENDED DECEMBER 31, 2019

RECONCILIATION OF REPORTED NET SALES % CHANGE TO CONSTANT CURRENCY % CHANGE

(unaudited)

2019

Q1

Q2

Q3

Q4

Year

Foreign

Constant

Foreign

Constant

Foreign

Constant

Foreign

Constant

Foreign

Constant

Reported %

Exchange

Currency***

Reported %

Exchange

Currency***

Reported %

Exchange

Currency***

Reported %

Exchange

Currency***

Reported %

Exchange

Currency***

Change

Impact

% Change

Change

Impact

% Change

Change

Impact

% Change

Change

Impact

% Change

Change

Impact

% Change

Geographic Results

Americas

(1.2)

%

(0.3)

%

(0.9) %

(0.2)

%

(0.3)

%

0.1

%

2.2

%

(0.1)

%

2.3

%

2.3

%

(0.1)

%

2.4

%

0.8

%

(0.2)

%

1.0

%

EMEA

(6.6)

(8.1)

1.5

(4.3)

(6.2)

1.9

0.7

(4.1)

4.8

(1.1)

(2.5)

1.4

(3.1)

(5.3)

2.2

Asia Pacific

1.4

(4.2)

5.6

0.8

(3.9)

4.7

8.9

0.1

8.8

9.2

0.6

8.6

5.1

(1.8)

6.9

Total

(2.1)

%

(2.8)

%

0.7

%

(0.9)

%

(2.1)

%

1.2

%

3.0

%

(0.9)

%

3.9

%

2.6

%

(0.6)

%

3.2

%

0.6

%

(1.6)

%

2.2

%

Product Categories

Knees

Americas

(3.1)

%

(0.2)

%

(2.9)

%

(1.0)

%

(0.1)

%

(0.9)

%

0.8

%

(0.1)

%

0.9

%

2.1

%

-

%

2.1

%

(0.3)

%

(0.1)

%

(0.2)

%

EMEA

(7.2)

(8.5)

1.3

(4.3)

(6.4)

2.1

0.7

(4.1)

4.8

(1.7)

(2.6)

0.9

(3.4)

(5.5)

2.1

Asia Pacific

2.2

(4.9)

7.1

1.4

(4.4)

5.8

8.5

(0.7)

9.2

5.5

-

5.5

4.3

(2.6)

6.9

Total

(3.4)

(3.1)

(0.3)

(1.4)

(2.5)

1.1

2.2

(1.0)

3.2

1.7

(0.6)

2.3

(0.3)

(1.8)

1.5

Hips

Americas

(0.3)

(0.4)

0.1

1.3

(0.3)

1.6

3.7

(0.1)

3.8

3.3

-

3.3

2.0

(0.2)

2.2

EMEA

(6.4)

(8.1)

1.7

(5.9)

(6.0)

0.1

1.1

(4.0)

5.1

(3.2)

(2.3)

(0.9)

(3.9)

(5.2)

1.3

Asia Pacific

1.7

(3.8)

5.5

(3.2)

(3.4)

0.2

5.1

0.7

4.4

9.1

1.0

8.1

3.2

(1.3)

4.5

Total

(1.7)

(3.4)

1.7

(1.6)

(2.5)

0.9

3.4

(0.9)

4.3

2.7

(0.4)

3.1

0.7

(1.8)

2.5

S.E.T*

0.7

(2.3)

3.0

1.4

(1.8)

3.2

6.3

(0.8)

7.1

5.8

(0.5)

6.3

3.5

(1.4)

4.9

Spine & Dental

(3.5)

(2.0)

(1.5)

(4.5)

(1.4)

(3.1)

(0.5)

(0.6)

0.1

(0.2)

(0.4)

0.2

(2.2)

(1.1)

(1.1)

Other

(2.3)

(2.6)

0.3

4.0

(1.9)

5.9

3.3

(0.5)

3.8

3.4

(0.4)

3.8

2.1

(1.3)

3.4

Total

(2.1)

%

(2.8)

%

0.7

%

(0.9)

%

(2.1)

%

1.2

%

3.0

%

(0.9)

%

3.9

%

2.6

%

(0.6)

%

3.2

%

0.6

%

(1.6)

%

2.2

%

* Sports Medicine, Extremities, Trauma and CMFT

** Net sales change information is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases. Management uses this non-GAAP financial measure internally to evaluate the performance of the business. Additionally, management believes this non-GAAP measure provides meaningful incremental information to investors to consider when evaluating the performance of the Company. Management believes this measure offers the ability to make period-to-period net sales comparisons that are not impacted by changes in foreign currency exchange rates. In addition, constant currency net sales changes are used as performance metrics in our incentive compensation programs.

ZIMMER BIOMET HOLDINGS, INC.

NET SALES % CHANGE - YEAR ENDED DECEMBER 31, 2020

RECONCILIATION OF REPORTED NET SALES % CHANGE TO CONSTANT CURRENCY % CHANGE

(unaudited)

2020

Q1

Q2

Q3

Q4

Year

Foreign

Constant

Foreign

Constant

Foreign

Constant

Foreign

Constant

Foreign

Constant

Reported %

Exchange

Currency***

Reported %

Exchange

Currency***

Reported %

Exchange

Currency***

Reported %

Exchange

Currency***

Reported %

Exchange

Currency***

Change

Impact

% Change

Change

Impact

% Change

Change

Impact

% Change

Change

Impact

% Change

Change

Impact

% Change

Geographic Results

Americas

(7.8)

%

(0.1)

%

(7.7)

%

(39.6)

%

(0.1)

%

(39.5)

%

3.2

%

(0.1)

%

3.3

%

(0.3)

%

-

%

(0.3)

%

(11.1)

%

(0.1)

%

(11.0)

%

EMEA

(14.2)

(2.5)

(11.7)

(50.1)

(1.1)

(49.0)

(2.3)

3.4

(5.7)

(13.2)

4.3

(17.5)

(20.4)

0.9

(21.3)

Asia Pacific

(10.4)

(0.9)

(9.5)

(18.6)

(0.4)

(18.2)

2.3

1.6

0.7

7.1

5.1

2.0

(4.5)

1.5

(6.0)

Total

(9.7)

%

(0.8)

%

(8.9)

%

(38.3)

%

(0.3)

%

(38.0)

%

2.0

%

0.9

%

1.1

%

(1.9)

%

1.8

%

(3.7)

%

(12.0)

%

0.4

%

(12.4)

%

Product Categories

Knees

Americas

(6.8)

%

-

%

(6.8)

%

(45.6)

%

-

%

(45.6)

%

2.7

%

-

%

2.7

%

0.3

%

-

%

0.3

%

(12.2)

%

-

%

(12.2)

%

EMEA

(13.1)

(2.7)

(10.4)

(60.1)

(0.8)

(59.3)

(6.9)

3.0

(9.9)

(19.5)

3.5

(23.0)

(25.4)

0.6

(26.0)

Asia Pacific

(11.7)

(1.5)

(10.2)

(30.1)

(0.7)

(29.4)

1.6

1.8

(0.2)

10.2

5.4

4.8

(7.5)

1.4

(8.9)

Total

(9.2)

(0.9)

(8.3)

(46.2)

(0.4)

(45.8)

0.5

1.0

(0.5)

(2.7)

1.7

(4.4)

(14.5)

0.3

(14.8)

Hips

Americas

(5.9)

(0.1)

(5.8)

(32.6)

(0.1)

(32.5)

7.9

(0.1)

8.0

1.0

-

1.0

(7.4)

(0.1)

(7.3)

EMEA

(16.4)

(2.5)

(13.9)

(43.7)

(1.2)

(42.5)

0.8

3.4

(2.6)

(12.2)

4.0

(16.2)

(18.4)

0.9

(19.3)

Asia Pacific

(14.0)

(0.5)

(13.5)

(11.3)

(0.2)

(11.1)

4.4

1.5

2.9

6.2

4.9

1.3

(3.4)

1.5

(4.9)

Total

(10.5)

(0.8)

(9.7)

(31.1)

(0.4)

(30.7)

5.4

1.0

4.4

(1.3)

2.1

(3.4)

(9.4)

0.5

(9.9)

S.E.T*

(6.2)

(0.7)

(5.5)

(28.4)

(0.5)

(27.9)

4.1

0.7

3.4

(0.5)

1.7

(2.2)

(7.7)

0.3

(8.0)

Spine & Dental

(13.4)

(0.5)

(12.9)

(40.9)

(0.2)

(40.7)

5.1

0.8

4.3

0.9

1.8

(0.9)

(12.2)

0.5

(12.7)

Other

(12.8)

(0.8)

(12.0)

(48.1)

(0.2)

(47.9)

(13.6)

0.9

(14.5)

(8.8)

1.7

(10.5)

(20.6)

0.4

(21.0)

Total

(9.7)

%

(0.8)

%

(8.9)

%

(38.3)

%

(0.3)

%

(38.0)

%

2.0

%

0.9

%

1.1

%

(1.9)

%

1.8

%

(3.7)

%

(12.0)

%

0.4

%

(12.4)

%

* Sports Medicine, Extremities, Trauma and CMFT

** Net sales change information is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases. Management uses this non-GAAP financial measure internally to evaluate the performance of the business. Additionally, management believes this non-GAAP measure provides meaningful incremental information to investors to consider when evaluating the performance of the Company. Management believes this measure offers the ability to make period-to-period net sales comparisons that are not impacted by changes in foreign currency exchange rates. In addition, constant currency net sales changes are used as performance metrics in our incentive compensation programs.

Disclaimer

Zimmer Biomet Holdings Inc. published this content on 04 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 May 2021 14:32:01 UTC.


© Publicnow 2021
All news about ZIMMER BIOMET HOLDINGS, INC.
07/15BACTIGUARD : Interim report for Q2 2021
AQ
07/06ZIMMER BIOMET : Announces Webcast and Conference Call of Second Quarter 2021 Fin..
PR
07/01ZIMMER BIOMET : Makes Milestone Payment to Sweden's Bactiguard After Trauma Impl..
MT
06/30BACTIGUARD : receives payment from Zimmer Biomet
AQ
06/25ZIMMER BIOMET HOLDINGS, INC. : Ex-dividend day for
FA
06/15BACTIGUARD : coated Zimmer Biomet trauma implants for infection prevention launc..
AQ
06/10Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2021, Payabl..
CI
06/07Zimmer Biomet Holdings Names Chief Science, Technology and Innovation Officer
MT
06/07Zimmer Biomet Announces New Appointments to Executive Leadership Team
CI
06/03Zimmer Biomet Holdings Seeks Acquisitions
CI
More news
Financials (USD)
Sales 2021 8 115 M - -
Net income 2021 1 063 M - -
Net Debt 2021 6 229 M - -
P/E ratio 2021 32,2x
Yield 2021 0,59%
Capitalization 34 070 M 34 070 M -
EV / Sales 2021 4,97x
EV / Sales 2022 4,54x
Nbr of Employees 20 000
Free-Float 66,7%
Chart ZIMMER BIOMET HOLDINGS, INC.
Duration : Period :
Zimmer Biomet Holdings, Inc. Technical Analysis Chart | ZBH | US98956P1021 | MarketScreener
Technical analysis trends ZIMMER BIOMET HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 31
Last Close Price 163,42 $
Average target price 190,46 $
Spread / Average Target 16,5%
EPS Revisions
Managers and Directors
Bryan C. Hanson Chairman, President & Chief Executive Officer
Suketu P. Upadhyay Chief Financial Officer & Executive Vice President
Zeeshan Tariq Chief Information Officer & Senior Vice President
Nitin Goyal Chief Science, Technology & Innovation Officer
Ivan Tornos Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ZIMMER BIOMET HOLDINGS, INC.6.05%34 070
ABBOTT LABORATORIES10.59%214 960
MEDTRONIC PLC11.56%176 468
BECTON, DICKINSON AND COMPANY2.21%74 377
ALIGN TECHNOLOGY, INC.30.21%55 063
SARTORIUS STEDIM BIOTECH65.28%52 629